<?xml version="1.0" encoding="UTF-8"?>
<p>Similarly, elvitegravir drug selections performed on four large cluster variants progressed more rapidly, leading to the first acquisition of the INSTI resistance mutations T66I (
 <italic>n </italic>=
 <italic> </italic>2), N155H (
 <italic>n </italic>=
 <italic> </italic>1) or S147G (
 <italic>n </italic>=
 <italic> </italic>1) at week 8, followed by the further accumulation of resistance mutations leading to viral escape (&gt;100-fold resistance) at weeks 23 and 36 (Figure
 <xref ref-type="fig" rid="dkx118-F3">3</xref>b). In contrast, elvitegravir selections performed on singleton/small cluster viral lineages were delayed with the first appearance of T66I as a singlet mutation occurring at week 23 in only two of four small cluster strains (Figure
 <xref ref-type="fig" rid="dkx118-F4">4</xref>b).
</p>
